花园生物
(300401)
| 流通市值：57.87亿 | | | 总市值：58.83亿 |
| 流通股本：5.33亿 | | | 总股本：5.42亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,484,764,656.55 | 1,502,869,900.27 | 1,766,021,826.73 | 1,929,355,187.95 |
| 应收票据及应收账款 | 131,551,942.75 | 92,775,888.26 | 155,357,591.1 | 186,407,125.63 |
| 应收账款 | 131,551,942.75 | 92,775,888.26 | 155,357,591.1 | 186,407,125.63 |
| 应收款项融资 | 950,000 | - | - | 765,200 |
| 预付款项 | 39,003,579.36 | 59,664,164.72 | 101,591,314.54 | 85,518,490.9 |
| 其他应收款合计 | 905,061.26 | 798,887.96 | 789,281.94 | 382,543.4 |
| 存货 | 787,350,465.97 | 780,039,441.34 | 689,726,529.33 | 653,139,069.97 |
| 其他流动资产 | 8,805,484.49 | 25,893,316.87 | 8,327,164.01 | 6,610,219.32 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,693,331,190.38 | 2,462,041,599.42 | 2,721,813,707.65 | 2,862,177,837.17 |
| 非流动资产: | | | | |
| 投资性房地产 | 65,884,662.13 | 66,349,484.29 | 66,814,306.45 | 73,210,455.22 |
| 固定资产 | 1,919,399,175.82 | 1,950,792,475.03 | 1,812,156,302.95 | 1,848,777,629.07 |
| 在建工程 | 551,643,294.35 | 504,592,950.84 | 597,746,215.51 | 552,270,954.95 |
| 无形资产 | 187,696,232.31 | 172,226,203.12 | 165,668,112.07 | 163,301,538.69 |
| 开发支出 | 13,074,434.34 | 24,518,973.56 | 27,768,893.73 | 30,653,202.61 |
| 递延所得税资产 | 39,220,546.12 | 40,407,574.4 | 37,996,030.81 | 35,672,831.57 |
| 其他非流动资产 | 50,749,663.24 | 39,662,807.41 | 45,710,525.38 | 37,908,851.8 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,827,668,008.31 | 2,798,550,468.65 | 2,753,860,386.9 | 2,741,795,463.91 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,520,999,198.69 | 5,260,592,068.07 | 5,475,674,094.55 | 5,603,973,301.08 |
| 流动负债: | | | | |
| 短期借款 | 639,589,722.26 | 408,678,541.69 | 811,334,106.9 | 873,724,708.32 |
| 交易性金融负债 | - | - | - | 428,100 |
| 应付票据及应付账款 | 300,336,890.83 | 327,871,804.59 | 351,491,352.07 | 384,548,684.29 |
| 其中：应付票据 | 16,864,280.76 | 20,437,907 | 28,001,983.11 | 27,651,734.18 |
| 应付账款 | 283,472,610.07 | 307,433,897.59 | 323,489,368.96 | 356,896,950.11 |
| 预收款项 | 1,882,528.74 | 1,671,932.31 | 1,967,669.03 | 1,867,669.92 |
| 合同负债 | 15,833,207.24 | 17,882,400.47 | 59,363,234.53 | 107,969,006.77 |
| 应付职工薪酬 | 11,045,788.11 | 33,362,780.03 | 19,687,335.84 | 18,980,276.69 |
| 应交税费 | 28,253,401.4 | 33,232,756.37 | 20,838,882.45 | 28,095,801 |
| 其他应付款合计 | 70,847,123.61 | 90,813,791.96 | 96,610,472.87 | 98,030,706.77 |
| 其中:应付利息 | - | - | 2,051,506.72 | 1,144,109.58 |
| 一年内到期的非流动负债 | 336,982,842.19 | 347,843,285.32 | 93,331,606 | 93,331,606 |
| 其他流动负债 | 2,052,689.12 | 2,313,722 | 7,695,410.41 | 14,015,481.22 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,406,824,193.5 | 1,263,671,014.74 | 1,462,320,070.1 | 1,620,992,040.98 |
| 非流动负债: | | | | |
| 应付债券 | 934,938,982.69 | 923,271,457.24 | 906,006,378.95 | 891,730,986.8 |
| 长期应付款 | 93,331,606 | 93,331,606 | 93,331,606 | 93,331,606 |
| 递延收益 | 36,444,922.09 | 42,524,547.68 | 56,671,393.73 | 58,328,967.6 |
| 递延所得税负债 | 44,053,842.46 | 44,663,175.41 | 260,868.3 | 366,860.78 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,108,769,353.24 | 1,103,790,786.33 | 1,056,270,246.98 | 1,043,758,421.18 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,515,593,546.74 | 2,367,461,801.07 | 2,518,590,317.08 | 2,664,750,462.16 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 541,702,388 | 551,009,084 | 551,008,522 | 551,007,557 |
| 其他权益工具 | 263,677,913.41 | 263,679,583.41 | 312,623,203.64 | 312,627,007.27 |
| 资本公积 | -91,063,307.27 | -7,610,140.17 | -14,828,612.56 | -22,014,500.52 |
| 减:库存股 | 26,861,765 | 140,415,591.33 | 74,771,059 | 53,723,530 |
| 盈余公积 | 217,247,880.01 | 217,247,880.01 | 191,916,483.04 | 191,916,483.04 |
| 未分配利润 | 2,100,702,542.8 | 2,009,219,451.08 | 1,991,135,240.35 | 1,959,409,822.13 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,005,405,651.95 | 2,893,130,267 | 2,957,083,777.47 | 2,939,222,838.92 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,005,405,651.95 | 2,893,130,267 | 2,957,083,777.47 | 2,939,222,838.92 |
| 负债和股东权益合计 | 5,520,999,198.69 | 5,260,592,068.07 | 5,475,674,094.55 | 5,603,973,301.08 |
| 公告日期 | 2024-04-16 | 2024-04-16 | 2023-10-21 | 2023-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |